Project Grant R01AI180093
Award Date
8/15/24
Completion Date
6/30/29
Dollars Obligated
$1.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award of $884,453.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid, cost-effective point-of-care (POC) test for detecting the hepatitis C virus (HCV). The project, titled "Rapid Point of Care Hepatitis C Virus Detection Using a Long-Lasting Luminescent Cascade Signal Amplification," is being conducted by Brigham & Women's Hospital...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,012,033 to the University of Washington to develop a point-of-care nucleic acid amplification test (NAAT) for rapid, on-site diagnosis of hepatitis C virus (HCV) infection. The proposed diagnostic test aims to address the challenge of delayed HCV testing and treatment by enabling same-day identification of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $876,400 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Notre Dame DU Lac to develop a novel point-of-care diagnostic assay for rapid assessment of hepatitis C virus (HCV) viral load and associated liver disease. The project aims to integrate Janus bead technology and virus ultrafiltration to create a 30-minute, one-step assay that can quantify HCV viral load...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a low-cost, instrument-free rapid antigen test for active Hepatitis C Virus (HCV) infection. The $272,133 award to Rutgers, The State University of New Jersey will fund research activities over a period of approximately 2 years, from June 2025 to May 2027. The key objectives are to characterize the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an integrated biosensor technology for the simultaneous detection of HIV, hepatitis B, and hepatitis C viruses. The $537,619 award, spanning from March 2025 to February 2028, will support the University of Central Florida's research to integrate their recently developed four-way junction (4WJ) electrochemical...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a proteomics atlas of HIV/HBV co-infections to support the discovery and validation of host factors and antivirals for a functional cure for hepatitis B virus (HBV). The $673,158 award to Emory University, with sub-awards to the University of Zurich and Weill Medical College of Cornell University, will...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...
This $194,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The project aims to use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent (the "shock") and then target the reactivated cells for elimination using adeno-associated virus (AAV) vectors expressing broadly...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $653,693 to Emory University to conduct research on the structural details of HIV-1 assembly and the mechanism of action of the capsid-targeting antiviral compound lenacapavir. The research aims to leverage cryo-electron microscopy and tomography techniques to investigate the molecular determinants and dynamics of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $510,306 to Emory University to conduct research on virus-host interactions for developing a cure against hepatitis B virus (HBV) infections. The research aims to advance the understanding of how HBV interacts with human host factors, with the goal of identifying new therapeutic approaches to achieve a functional...